More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality
Veeva Systems (NYSE: VEEV) announced that over 75 biotechnology companies are now using Veeva Basics, their pre-configured and pre-validated software solution for clinical, regulatory, and quality operations. The company has introduced two new applications: Veeva CTMS Basics for clinical trial management and Veeva Submissions Publishing Basics for regulatory submissions.
The rapid adoption indicates a market shift from basic tools to comprehensive solutions that can scale with company growth. Available in North America and Europe, these solutions enable biotechs to deploy industry-leading software within weeks. Built on the Vault Platform, Veeva Basics allows customers to maintain current features and adapt their technology infrastructure as they expand.
Veeva Systems (NYSE: VEEV) ha annunciato che oltre 75 aziende biotecnologiche stanno utilizzando Veeva Basics, la loro soluzione software preconfigurata e prevalidata per le operazioni cliniche, regolatorie e di qualità. L'azienda ha lanciato due nuove applicazioni: Veeva CTMS Basics per la gestione degli studi clinici e Veeva Submissions Publishing Basics per le sottomissioni regolatorie.
L'adozione rapida evidenzia un cambiamento di mercato verso soluzioni complete che possano crescere insieme all'azienda. Disponibili in Nord America ed Europa, queste soluzioni permettono alle biotecnologie di implementare software all'avanguardia in poche settimane. Basato sulla Vault Platform, Veeva Basics consente ai clienti di mantenere le funzionalità attuali e adattare l'infrastruttura tecnologica durante l'espansione.
Veeva Systems (NYSE: VEEV) anunció que más de 75 compañías biotecnológicas están utilizando Veeva Basics, su solución de software preconfigurada y prevalidada para operaciones clínicas, regulatorias y de calidad. La empresa ha presentado dos nuevas aplicaciones: Veeva CTMS Basics para la gestión de ensayos clínicos y Veeva Submissions Publishing Basics para presentaciones regulatorias.
La rápida adopción indica un cambio en el mercado desde herramientas básicas hacia soluciones integrales que pueden escalar con el crecimiento de la compañía. Disponibles en Norteamérica y Europa, estas soluciones permiten a las biotecnológicas implementar software líder en la industria en cuestión de semanas. Construido sobre la Vault Platform, Veeva Basics permite a los clientes mantener las funcionalidades actuales y adaptar su infraestructura tecnológica a medida que crecen.
Veeva Systems (NYSE: VEEV)는 현재 75개 이상의 바이오테크 기업이 임상, 규제 및 품질 운영을 위한 사전 구성 및 사전 검증된 소프트웨어 솔루션인 Veeva Basics를 사용하고 있다고 발표했습니다. 회사는 임상 시험 관리를 위한 Veeva CTMS Basics와 규제 제출을 위한 Veeva Submissions Publishing Basics라는 두 가지 새로운 애플리케이션을 도입했습니다.
빠른 채택은 기본 도구에서 회사 성장에 맞춰 확장 가능한 종합 솔루션으로 시장이 전환하고 있음을 나타냅니다. 북미 및 유럽에서 제공되는 이 솔루션들은 바이오테크 기업들이 수주 내에 업계 선도 소프트웨어를 배포할 수 있도록 지원합니다. Vault 플랫폼 위에 구축된 Veeva Basics는 고객이 현재 기능을 유지하고 확장에 따라 기술 인프라를 조정할 수 있게 합니다.
Veeva Systems (NYSE: VEEV) a annoncé que plus de 75 entreprises biotechnologiques utilisent désormais Veeva Basics, leur solution logicielle préconfigurée et prévalidée pour les opérations cliniques, réglementaires et qualité. La société a lancé deux nouvelles applications : Veeva CTMS Basics pour la gestion des essais cliniques et Veeva Submissions Publishing Basics pour les soumissions réglementaires.
Cette adoption rapide reflète un changement de marché, passant des outils basiques à des solutions complètes capables de s'adapter à la croissance des entreprises. Disponibles en Amérique du Nord et en Europe, ces solutions permettent aux biotechs de déployer des logiciels de pointe en quelques semaines. Basé sur la plateforme Vault, Veeva Basics permet aux clients de conserver les fonctionnalités actuelles et d'adapter leur infrastructure technologique au fur et à mesure de leur expansion.
Veeva Systems (NYSE: VEEV) gab bekannt, dass über 75 Biotechnologieunternehmen nun Veeva Basics nutzen, ihre vorkonfigurierte und vorvalidierte Softwarelösung für klinische, regulatorische und Qualitätsprozesse. Das Unternehmen hat zwei neue Anwendungen eingeführt: Veeva CTMS Basics für das Management klinischer Studien und Veeva Submissions Publishing Basics für regulatorische Einreichungen.
Die schnelle Akzeptanz zeigt einen Marktwechsel von einfachen Werkzeugen hin zu umfassenden Lösungen, die mit dem Unternehmenswachstum skalieren können. Verfügbar in Nordamerika und Europa ermöglichen diese Lösungen Biotech-Firmen, branchenführende Software innerhalb weniger Wochen einzusetzen. Basierend auf der Vault-Plattform erlaubt Veeva Basics den Kunden, bestehende Funktionen beizubehalten und ihre technologische Infrastruktur mit dem Wachstum anzupassen.
- Over 75 biotech companies have adopted Veeva Basics, showing strong market penetration
- Expansion of product portfolio with two new applications (CTMS Basics and Submissions Publishing Basics)
- Geographic presence in both North America and Europe markets
- Platform designed for scalability, allowing companies to grow without changing systems
- None.
Insights
Veeva's Basics platform gaining significant traction with 75+ biotechs; expansion signals growth in small-to-midsize customer segment.
Veeva Systems' announcement represents a significant milestone in their market penetration strategy targeting emerging biotechs. The 75+ customer adoption figure demonstrates Veeva's successful downmarket expansion beyond their traditional enterprise client base. This approach addresses a critical market gap where smaller biotechs previously had to choose between inadequate entry-level tools or enterprise solutions they couldn't afford or fully utilize.
The two new applications - CTMS Basics for clinical trial management and Submissions Publishing Basics for regulatory submissions - strategically expand Veeva's footprint in the clinical and regulatory domains. These offerings extend Veeva's revenue opportunities within each customer while addressing critical operational pain points for emerging biotechs.
What's particularly shrewd about this "Basics" approach is how it creates a natural upgrade path for growing companies. By standardizing on pre-configured, pre-validated versions of Veeva's enterprise solutions, the company establishes valuable customer relationships early, positioning itself to capture increasing revenue as these biotechs scale. The "land and expand" strategy is evident in how these solutions are designed to grow alongside customer needs.
Customer testimonials from Corbus Pharmaceuticals, Scancell, and Terns Pharmaceuticals validate the value proposition, highlighting operational efficiency gains, regulatory compliance benefits, and implementation speed - all crucial factors for resource-constrained biotechs. The emphasis on geographic expansion across North America and Europe indicates broad market acceptance rather than regional success.
This announcement signals Veeva's effective execution against competition from both less sophisticated point solutions and larger enterprise software players attempting to move downmarket.
Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies
Designed specifically for fast-growing companies, Veeva Basics provides pre-configured and pre-validated solutions. This enables fast deployment and adoption regardless of company size. With clinical, regulatory, and quality solutions available, Veeva is adding two new applications for biotechs:
- Veeva CTMS Basics for clinical trial management, including milestones, monitoring, enrollment, issue resolution, and site communications.
- Veeva Submissions Publishing Basics for building, publishing, and transmitting regulatory submissions in a single system.
"More biotechs are adopting Veeva Basics in
Veeva CTMS Basics and Submissions Publishing Basics are available today in
What biotechs are saying about Veeva Basics:
"I believe Veeva Basics is a game changer, giving smaller biotech companies access to the same modern and connected applications that are typically only available to larger organizations," said Ian Hodgson, Ph.D., chief operating officer at Corbus Pharmaceuticals, Inc. "As our company continues to grow, I am confident that Veeva's platform can scale with us and help ensure we remain up to date as regulatory requirements evolve."
"As we expand our studies to a larger scale, Veeva eTMF Basics gives us more control of our data and process to ensure inspection readiness," said Joe Thornton, associate director, clinical operations at Scancell. "Having an industry-leading solution with pre-configured best practices as our foundation for trials will help drive speed and innovation as we continue to develop novel immunotherapies."
"The global support and training provided with Veeva Basics helps us gain maximum value from Veeva's industry solution," said Rebecca Deng, Ph.D., associate director, regulatory affairs and QA systems at Terns Pharmaceuticals. "With a simple path to go live and validation, Veeva Basics has delivered significant time and resource savings."
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-75-emerging-biotechs-use-veeva-basics-across-clinical-regulatory-and-quality-302460294.html
SOURCE Veeva Systems
FAQ
What is Veeva Basics and how many companies are using it?
What are the new applications launched by Veeva Systems (VEEV)?
Where is Veeva Basics available and how quickly can it be deployed?
How does Veeva Basics help growing biotech companies?
